<DOC>
	<DOCNO>NCT01267747</DOCNO>
	<brief_summary>Primary objective PAPPHY Study establish prevalence primary aldosteronism ( PA ) consecutive hypertensive patient hospitalize lone ( non valvular ) , paroxysmal , persistent permanent atrial flutter fibrillation ( AFF ) . Secondary objective identify : 1. clinical , echocardiographic biochemical predictor AFF hypertensive patient with/without PA ; 2. AFF , increase ANP and/o BNP thereby conceivably blunt aldosterone secretion , low ARR impede PA detection . 3. usefulness aldosterone-to-renin ratio ( ARR ) base plasma renin activity ( PRA ) direct measurement renin ( DRA ) diagnose PA patient AFF . 4. rate recurrence new onset AFF follow-up cohort hypertensive patient with/without PA function specific treatment latter . Design : cohort multicenter prospective study . Sample size : 1000 consecutive patient . Procedure At baseline cardiac function , arterial stiffness , plasma renin activity ( PRA ) , direct renin assay ( DRA ) , plasma aldosterone ( PAC ) measure . Pharmacologic direct current cardioversion ( DCC ) perform indicate accord 2010 ESC guideline . PRA PAC measure 2 week cardioversion answer secondary aim b . If ARR &gt; 26 PAC &gt; 15 ng/dL , adrenal vein sampling ( AVS ) perform patient willing undergo adrenalectomy identify lateralized PAC excess . Follow-up aim assess damage organ , occurrence cardiovascular event recurrence AFF patient without PA . Demonstration high prevalence PA patient AFF compare general population hypertensive subject provide evidence 1 ) role aldosterone excess cause AFF cardiac electric remodeling ; 2 ) usefulness case detection PA hypertensive patient AFF ; 3 ) predictor AFF ; 4 ) outcome specific treatment PA risk incident recurrent AFF .</brief_summary>
	<brief_title>Prevalence Primary Aldosteronism Hypertensive Patients Presenting With Atrial Flutter Fibrillation</brief_title>
	<detailed_description>A previous retrospective study document 12-fold increase risk AFF patient primary aldosteronism ( PA ) compare subject primary ( essential ) hypertension ( Milliez 2005 ) . However , retrospective investigation could involve selection bias therefore regarded hypothesis-generating rather proof-of-concept study . Hence , base result experimental study , hypothesize proportion hypertensive patient present lone ( non valvular ) PA could underlie cause hypertension lead AFF . If prove , hypothesis would imply early diagnosis PA might cure PA hypertension also prevent AFF non negligible number hypertensive patient . Primary objective establish prevalence PA consecutive hypertensive patient hospitalize lone ( non valvular ) , paroxysmal , persistent permanent AFF . Secondary objective identify : 1. clinical , echocardiographic , biochemical predictor AFF hypertensive patient with/without PA ; 2. AFF increase ANP and/or BNP , thereby conceivably blunt aldosterone secretion , low ARR impede detection PA ; 3. usefulness aldosterone-to-renin ratio ( ARR ) base either plasma renin activity ( PRA ) direct measurement active renin ( DRA ) diagnose PA patient AFF ; 4. prospectively rate recurrence AFF follow-up cohort hypertensive patient with/without PA correction PA adrenalectomy mineralocorticoid receptor antagonists pharmacological treatment essential hypertension . Study design : Prospective multicenter cohort study . Enrolment Sites : Internal Medicine , Cardiology , Endocrinology locate Europe . These center constitute network PAPY ( Primary Aldosteronism Prevalence Hypertension ) Study ENS @ T ( European Network Study Adrenal Tumors ) . Sample size : Based PAPY study experience available data literature concern prevalence study , anticipated enrolment least 1000 consecutive patient give conclusive evidence PA prevalence AFF patient . Data analysis . Data collect use specific software ; database securely store analyze core laboratory Clinica Medica 4-DMCS Padova , Italy . Experimental Procedures . Baseline visit ( visit 1 ) - Clinic evaluation patient ; - Collection demographic data history ; - Measurement blood pressure heart rate ; - Scanning storage ECG document AFF ; - Echocardiography measurement leave atrial aortic diameter , leave ventricular thickness diameter , systolic diastolic transmitral Doppler flow velocity index ; - Measurement pulse wave velocity ankle-brachial index EcoDoppler assessment regional arterial stiffness ; - Clinical chemistry include serum ion , s-Creatinine , GFR calculate MDRD formula , HbA1c , microalbuminuria , S-proBNP , ANP , TSH , SNP identification ; - Measurement PRA plasma aldosterone concentration ( PAC ) , baseline captopril challenge , patient assume drug interfere renin angiotensin system eventually correction hypokalemia ; - Cardioversion accord 2010 ESC guideline . In patient assume drug interfere renin angiotensin-aldosterone system , drug withdraw therapy verapamil , diltiazem , amiodarone start heart rate control . α2 agonist add , necessary , achieve BP control . Visit 2 . If perform visit 1 , PRA , DRA PAC measure basal condition captopril challenge . Visit 3 . Two week cardioversion , PRA , DRA plasma aldosterone measure baseline captopril challenge calculate ARR-P ARR-D . If baseline ARR-P &gt; 26 PAC &gt; 15 ng/dL , either and/or cardioversion , image adrenal gland CT perform exclude adrenocortical carcinoma . The patient plausible candidate general anesthesia willing undergo adrenalectomy case detection lateralize excess aldosterone production , offer AVS . If patient satisfy criterion receive spironolactone potassium canrenoate , alone combination antihypertensive medication appropriate , order achieve target BP level risk . If ARR-P &lt; 20 PAC &gt; 15 ng/dL basal condition , PA may exclude patient enter follow-up investigation . Visit 4 . AVS use diagnosis bilaterally selective ( Selectivity Index &gt; 1.1 ) lateralization diagnose Lateralization Index &gt; 2 . In case lateralize excess aldosterone production , adrenalectomy plan . Follow-Up . Follow-up aim assess damage organ , occurrence cardiovascular event , include recurrence AFF patient without PA . Visits schedule every 6 month 2 year . BP , HR biochemical parameter measure , EKG echocardiography record .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>Unequivocal evidence ( ECG , Holter ECG medical chart ) AFF ( paroxysmal , persistent permanent ) patient blood pressure &gt; 140/90 mmHg least 3 office measurement , current use antihypertensive drug ; Written inform consent . Patient refusal participate study ; Moderatesevere valvular congenital myocardial heart disease ; Current abnormal thyroid function ; Chronic renal failure ( sCreatinine &gt; 200 μM eGFR &lt; 40 ml/min , calculate MDRD formula ) ; Hemochromatosis ; Alcohol abuse ; Acute coronary syndrome , history CABG , PTCA with/without stenting , acute myocardial infarction ; Hepatitis C virus and/or B and/or HIV infection ; Pheochromocytoma know secondary form arterial hypertension ; Hemodynamic instability preclude withdrawal drug ( e.g . βblockers , ARBs , ACEI , diuretic ) , interfere PRA ( DRA ) aldosterone measurement . Patients resistant hypertension antihypertensive drug treatment withdrawal/modifications consider unsafe investigated treatment , necessary , submit AVS exclude lateralize cause aldosterone excess . They analyze separate group .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Atrial Flutter</keyword>
	<keyword>Primary Aldosteronism</keyword>
	<keyword>Aldosterone Producing Adenoma</keyword>
</DOC>